As 2025 comes to a close, healthcare is already being shaped by a series of high-impact developments cutting across clinical specialties.

, the ninth edition of our annual series, will reflect on the breakthroughs, challenges, and evolving conversations across healthcare. This year’s coverage will deliver a new installment every evening Monday through Friday, for the entire month of December, featuring in-depth features, expert commentary, podcasts, and dynamic multimedia content highlighting the most impactful developments in medicine from across the HCPLive Network.

This year’s series brings together perspectives on major advances across specialties, including progress in liver disease, evolving treatable traits in COPD and asthma, and continued shifts in diabetes care. Nephrology takes a central role with updates on rare kidney diseases and new insights on kidney stones, while metabolic health stays at the forefront through coverage of GLP-1 therapies reshaping cardiology, neurology, and other specialties as well as new obesity research following the latest Lancet Commission findings. 

Additional installments examine rising interest in nonhormonal options for vasomotor symptoms, renewed national attention on cancer screening after President Joe Biden’s prostate cancer diagnosis, the impact of falling vaccination rates and health misinformation, and key developments in dermatology, xenotransplantation, pulmonary screening, multiple sclerosis biomarkers, vaccine policy, and oral immunotherapy.

This edition will also feature new episodes of HCPLive’s flagship podcasts, including 

, adding expert-driven conversation to the mix.

Together, these stories and discussions carry forward the momentum of 2025 and illustrate how medicine continues to evolve as we head into 2026.

This year’s series is a collaboration across the HCPLive Network:

 on Facebook, Twitter, and LinkedIn using the hashtag 

, or follow the series on HCPLive’s homepage and daily newsletter.

A full list of entries and summaries will be available as the series unfolds. Check back throughout December for new installments and insights as we look toward 2026.

Articles

The healthcare landscape in 2025 is being shaped by significant developments across various clinical specialties. The ninth edition of "This Year in Medicine" will provide a comprehensive review of these advancements, featuring daily installments throughout December. Key areas of focus include liver disease, COPD, asthma, diabetes care, nephrology, and metabolic health. The series will also address nonhormonal treatments for vasomotor symptoms, cancer screening, vaccination rates, and health misinformation. Expert commentary and multimedia content will enhance the coverage, offering insights into the evolving field of medicine as we approach 2026.

Explore groundbreaking advancements in healthcare as 2025 concludes, featuring expert insights and dynamic multimedia. 

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

This Year In Medicine

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Hepatology

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

This Year in Medicine 2025: Recognizing Top Advances in Healthcare

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

On November 10, 2025, InflaRx reported positive phase 2a preliminary results showing that its oral C5aR inhibitor INF904 produced rapid, meaningful clinical improvements in both hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) with no safety signals.

 These findings prompt plans to advance the therapy into phase 2b development.

“Results from our Phase 2a study indicate INF904’s positive safety profile to date and show promising signals of clinical benefit…” said Camilla Chong, MD, chief medical officer of InflaRx, in a statement.

 “We are particularly proud to have advanced this study to this stage in less than a year from study start, which was made possible thanks to the dedication of our clinical team and the excellent collaboration with investigators and their patients.”

INF904, an oral small-molecule C5aR1 inhibitor, has previously demonstrated anti-inflammatory activity, strong safety, minimal CYP3A4/5 interaction, and sustained ≥90% C5a blockade in first-in-human studies. InflaRx assessed the safety and the pharmacokinetics/pharmacodynamics profile of INF904 across 31 patients with HS and 31 with CSU in an 8-week multicenter, open-label trial. Efficacy served as an exploratory endpoint.

Investigators evaluated multiple INF904 dosing regimens (60 mg, 90 mg, and 120 mg) over 4 weeks of treatment, with an additional 4-week follow-up period where patients are not dosed with INF904. The study is ongoing, and investigators are working to complete the 4-week post-treatment observation period.

“As we move toward initiating phase 2b in HS and broadening the INF904 clinical program in CSU and beyond, we look forward to further validating INF904’s differentiated profile and advancing its development for patients in need,” said Niels C. Riedemann, chief executive officer and founder of InflaRx.

Data on INF904 for Hidradenitis Suppurativa

InflaRx reported INF904 efficacy data from 29 patients with HS across all 3 dosing arms who completed 4 weeks of treatment: 10 on 60 mg, 11 on 90 mg, and 8 on 120 mg.

 The study also has additional data from 25 patients who had completed the subsequent 4-week follow-up observation period.

HS endpoints included the reduction in d combined abscesses + nodules (AN) and draining tunnel (dT) counts, achievement of hidradenitis suppurativa clinical response (HiSCR), pain reduction (Numeric Rating Scale 30 (NRS30)), and improvement in the Dermatology Life Quality Index (DLQI). INF904 led to rapid, meaningful improvements in these endpoints at week 1, with continued improvement over the 4-week treatment period. All doses demonstrated positive clinical activity, with the 120 mg dose appearing to be the most effective.

“These data in hidradenitis suppurativa (HS) are encouraging, demonstrating the potential for INF904 to rapidly and substantially reduce total inflammatory burden (TIB) - abscesses, nodules, and draining tunnels,” said John Ingram, clinical professor & consultant dermatologist at Cardiff University and specialty lead for dermatology, health and care research Wales, in a statement.

 “These findings suggest INF904 could meaningfully lessen the burden faced by HS patients, many of whom continue to suffer despite the relatively small set of approved therapies currently available.”

Data from the 25 patients who completed the 4-week observation period showed that HiSCR responses continued to improve even 4 weeks after treatment ended. PK results from week 8 indicate that INF904 levels remain sufficient to provide C5aR-blocking potential 4 weeks after discontinuation. Supporting this, an additional study found that INF904 maintains > 90% blocking of C5a-induced neutrophil activation at disease-relevant C5a levels 24 hours after dosing across the 30–240 mg range.

Safety data was reported in 33 patients with HS. The study did not detect safety concerns or serious adverse events (SAEs).

The study reported 3 adverse events in 2 patients that were considered “possibly-to-likely related to drug” but were mild in nature.

“Given the pressing need for novel mechanisms of action, and INF904’s emerging clinical profile as a well-tolerated and potentially effective oral therapy, I am optimistic about its advancement into later-stage development and its potential to address an important unmet need in HS,” Ingram said.

The study reported efficacy data on INF904 in 30 patients with CSU (14 on 60 mg and 16 on 120 mg). The study also had additional data from 23 patients who completed the observation period. Endpoints included change from baseline in UAS7, UCT7, and responder rate analyses.

Reported UAS7 improvements were greatest in the 60-mg cohort (-13.7 points at week 4), exceeding historical placebo responses and falling within the range of approved CSU therapies. Among patients with severe CSU at baseline (n = 23), the 60-mg dose reduced UAS7 by 15.4 points, and in those with angioedema (n = 3), by 18.7 points. INF904 also appeared similarly effective in patients with high (n = 22) and low (n = 6) baseline IgE.

In the 23 CSU patients who completed a 4-week off-drug follow-up, clinical benefit persisted, with the 60-mg group showing a mean UAS7 reduction of 16.7 points.

Safety data from 33 patients showed no concerns: no SAEs were reported, and only one mild, possibly drug-related adverse event occurred.

“The Phase 2a data for INF904 in chronic spontaneous urticaria (CSU) are encouraging, indicating clinical activity and safety,” said Martin Metz, MD, professor of dermatology and deputy director of the Institute of Allergology | Charité at Universitätsmedizin, in Germany, in a statement. “…by inhibiting the C5a receptor, INF904 appears to be acting on the inflammation environment underlying urticaria, which may further benefit from continued dosing. Given the unmet need in CSU, and the potential for INF904 as an effective and safe oral agent to benefit a significant number of patients, further exploration in CSU is clearly warranted.”

11-2025-InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurativa (HS) and Chronic Spontaneous Urticaria (CSU). Inflarx.de. Published 2025. Accessed December 1, 2025. https://www.inflarx.de/Home/Investors/Press-Releases/11-2025-InflaRx-Reports-Positive-Phase-2a-Data-for-INF904-in-Hidradenitis-Suppurativa--HS--and-Chronic-Spontaneous-Urticaria--CSU-.html

Press Release. Inflarx.de. Published 2023. Accessed December 1, 2025. https://www.inflarx.de/Home/Investors/Press-Releases/Press-Release~2023-09-InflaRx-Announces-Positive-Topline-Results-from-the-Single-Ascending-Dose--SAD--Phase-I-Study-with-C5aR-Inhibitor-INF904~.html

InflaRx's oral C5aR inhibitor, INF904, demonstrated promising phase 2a results in treating hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU), showing rapid clinical improvements without safety concerns. The study involved multiple dosing regimens and showed sustained efficacy even after treatment cessation. In HS, INF904 reduced inflammatory burden and improved quality of life metrics, while in CSU, it significantly decreased UAS7 scores. The findings support advancing INF904 to phase 2b trials, highlighting its potential as a well-tolerated, effective oral therapy for these conditions.

The oral C5aR inhibitor produced durable responses across multiple doses in an 8-week trial, prompting InflaRx to move forward with phase 2b development.


INF904 Shows Strong Phase 2a Results in HS and CSU, With No Safety Signals

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

US Food and Drug Administration | Image Credit: US Food and Drug Administration

The US Food and Drug Administration (FDA)

 has accepted a supplemental New Drug Application (sNDA) for the FUROSCIX ReadyFlow Autoinjector (SCP-111), which delivers a subcutaneous injection of furosemide in <10 seconds to treat edema in patients with 

Announced on December 1, 2025, by parent company MannKind Corporation, this acceptance was supported in part by positive study results announced in August 2024, which compared a furosemide treatment via SCP-111 to the FDA-approved FUROSCIX On-body Infusor. If approved, SCP-111 could reduce administration time from 5 hours to under 10 seconds.

“By delivering treatment in under 10 seconds, the ReadyFlow Autoinjector has the potential to transform how adults with chronic heart failure or chronic kidney disease manage episodes of fluid buildup—providing faster relief, reducing hospital admissions, and lowering overall healthcare costs,” Michael Castagna, PharmD, chief executive officer at MannKind Corporation, said in a statement. “We are excited about the opportunity to bring this innovation forward and empower patients with greater convenience and control in their treatment journey.”

The study in question was an open-label, single-center, single-dose, randomized, 2-way crossover study conducted by scPharmaceuticals. Patients were included if they were between the ages of 45 and 80. Patients were excluded if they exhibited systolic blood pressure <90 mmHg at screening or baseline, a heart rate >110 BPM, serum potassium <3 or >5.5 mEq/L at screening, or other significant cardiac abnormalities, among other factors.

A total of 21 patients were included in the trial, who were then randomly assigned in a 1:1 ratio to either IV furosemide followed by SCP-111 via the autoinjector or vice versa. Each patient completed the screening, baseline, treatment, and follow-up phases of the trial. Full data from the trial will be presented at a forthcoming medical meeting or publication but has not been released yet.

Ultimately, SCP-111 showed a bioavailability of 107.3% (90% CI, 103.9-110.8), achieving the 90% confidence interval limit of 80-125%. Additionally, participants who received SCP-111 had similar urine output, urinary sodium excretion, and urinary potassium excretion at 6, 8, and 12 hours compared to IV furosemide. Patients reported a median pain score of 0 across all time points assessed, and the most common adverse events with SCP-111 were localized to the injection site and were consistent with those reported in the prescribing information for intravenous and oral furosemide.

“If approved, we believe administration of furosemide via an autoinjector would provide treatment flexibility to cardiologists and heart failure specialists and their patients,” John Tucker, chief executive officer of scPharmaceuticals, said in a statement.

SCP-111 has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of July 26, 2026.

MannKind Therapeutics. MannKind Announces US FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease. GlobeNewswire. December 1, 2025. Accessed December 1, 2025. 

https://www.globenewswire.com/news-release/2025/12/01/3196982/29517/en/MannKind-Announces-U-S-FDA-Accepts-for-Review-its-Supplemental-New-Drug-Application-sNDA-of-FUROSCIX-ReadyFlow-Autoinjector-for-the-Treatment-of-Edema-in-Adults-with-Chronic-Heart-.html

scPharmaceuticals, Inc. Pharmacokinetics and Pharmacodynamics of Subcutaneous vs Intravenous Furosemide in Healthy Volunteers. ClinicalTrials.gov identifier: NCT06167707. Updated June 27, 2024. Accessed December 1, 2025. 

https://clinicaltrials.gov/study/NCT06167707

scPharmaceuticals, Inc. scPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1mL) Autoinjector. GlobeNewswire. August 12, 2024. Accessed December 1, 2025. 

https://www.globenewswire.com/news-release/2024/08/12/2928204/0/en/scPharmaceuticals-Announces-Positive-Topline-Study-Results-for-SCP-111-Furosemide-80-mg-1-mL-Autoinjector.html

The FDA has accepted a supplemental New Drug Application for the FUROSCIX ReadyFlow Autoinjector, which delivers furosemide subcutaneously in under 10 seconds for treating edema in chronic heart failure or kidney disease patients. This innovation could significantly reduce administration time compared to the existing FUROSCIX On-body Infusor. A study demonstrated SCP-111's bioavailability and comparable efficacy to IV furosemide, with minimal adverse events. The autoinjector offers potential treatment flexibility and convenience, with a Prescription Drug User Fee Act target action date set for July 26, 2026.

The acceptance comes on the heels of positive topline results comparing the new device to the current on-body infusor.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Chronic Kidney Disease

FDA News

FDA Accepts sNDA for Furosemide Autoinjector for Chronic Heart Failure and CKD

Sayna Norouzi, MD, is an assistant professor of medicine and clinical nephrologist at Loma Linda University Medical Center

Factor D Inhibition Lacks Efficacy For IgAN in Phase 2 ALXN2050 Trial, With Sayna Norouzi 

New data from the phase 2 study of ALXN2050 (vemircopan) showed a non-statistically significant urine protein reduction compared to placebo, suggesting factor D inhibition is not an effective therapy for 

Findings from the randomized, placebo-controlled phase 2 trial of ALXN2050, presented by study investigator Sayna Norouzi, MD, an assistant professor of medicine and clinical nephrologist at Loma Linda University Medical Center, at the 

American Society of Nephrology Kidney Week 2025

, showed a clear lack of efficacy and signaled emerging safety concerns in adults with IgAN.¹

With an evolving understanding of the pathogenesis of IgAN, clinical research has investigated the potential of immune and complement-targeted therapies to change the disease course. In line with this, ALXN2050 is an oral small-molecule designed for the selective inhibition of factor D, a serine protease largely produced in adipocytes, and the rate-limiting enzyme in the activation sequence of the alternative pathway.

“Since iptacopan showed significant benefits and aligns with our understanding of IgAN pathophysiology, it made sense to evaluate a factor D inhibitor in IgAN to see whether it could interrupt the disease process at Hit 4,” Norouzi said in an interview with 

. “But early data from this study suggest we should not continue pursuing a factor D inhibitor in IgAN.”

In the 26-week initial evaluation period, participants who were diagnosed with IgAN, had urine protein ≥1 g/d, an estimated glomerular filtration rate (eGFR) of >30 mL/min/1.73m2, and were on stable renin-angiotensin system inhibitors were randomly assigned in a 3:1:3 ratio to ALXN2050 180mg, ALXN2050 120mg, or placebo. Investigators measured the primary endpoint as the percent change in urine protein from baseline to week 26, through 24-hour urine collection.

Of the 61 enrolled patients, 47 (77.0%) completed the initial evaluation period. At baseline, mean urine protein was similar between the ALXN2050 and placebo groups (2.2 vs 2.1 g/d), as was mean eGFR (65.9 vs 70.6 mL/min/1.73m²).

By week 26, patients receiving ALXN2050 180 mg had a 26.2% reduction in urine protein compared with a 10.3% reduction with placebo, corresponding to a relative treatment effect of −17.7% (90% CI, −37.5% to 8.3%), with similar findings in sensitivity analyses. When all ALXN2050 doses were combined, the relative treatment effect was −18.6% (90% CI, −37.0% to 5.1%).

Investigators paused the phase 2 study after a serious adverse event in the lupus nephritis cohort, with a patient exhibiting jaundice and marked liver enzyme elevation consistent with acute hepatic failure, resulting in a fatal outcome. Ultimately, the trial was terminated with concerns regarding confounded data when it came to re-initiating dosing.

In the IgAN cohort, most adverse events during the initial evaluation period were mild and unrelated to treatment, and no serious treatment-related adverse events or discontinuations occurred. However, during the extension period, a patient receiving ALXN2050 180 mg experienced liver enzyme elevation with a positive rechallenge signal.

“It’s also important to talk about trials like this. We often hear about positive results and successful recruitment, but many trials encounter safety issues or disappointing efficacy,” said Norouzi. “These trials still matter; they help us learn, refine study design, and understand which therapeutic pathways are worth pursuing. This is how we continue navigating treatment development in IgA nephropathy.”

Editors’ note: Norouzi has relevant disclosures with Calliditas, Novartis, Otsuka, and Boehringer Ingelheim.

Roccatello D, Sayna Norouzi, Mohsen El Kossi, et al. Efficacy and Safety of ALXN2050 in IgAN: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. 

Journal of the American Society of Nephrology

‌Caravaca-Fontán F, Gutiérrez E, Sevillano ÁM, Praga M. Targeting complement in IgA nephropathy. 

Videos

The phase 2 study of ALXN2050 in IgAN did not meet its proteinuria endpoint, with emerging safety concerns and early termination.


Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Factor D Inhibition Lacks Efficacy For IgAN in Phase 2 ALXN2050 Trial, With Sayna Norouzi, MD 

Rachel Rosovsky, MD, is a hematologist and clinical investigator at the Massachusetts General Hospital and associate professor at Harvard Medical School.

CAVT With Anticoagulation Substantially Reduces RV/LV Diameter Ratio in PE, With Rachel Rosovsky, MD

Results from the STORM-PE trial have highlighted the superior efficacy of computer-assisted vacuum thrombectomy (CAVT) with anticoagulation (AC) in reducing right-to-left-ventricular (RV/LV) diameter ratio within 48 hours compared to AC alone in patients with intermediate to high risk of 

The elevated RV/LV diameter ratio characteristic of PE can often result in early clinical decompensation and mortality. The disease affects 1 in 1000 adults worldwide annually, reflecting a substantial reduction to quality of life. AC alone has long been considered the core of PE treatment, but growing evidence endorses endovascular therapy coupled with AC as a safe and effective method of reducing the RV/LV ratio. STORM-PE is the first randomized clinical trial to test the efficacy and safety of a mechanical thrombectomy against AC.

 sat down with Rachel Rosovsky, MD, a hematologist and clinical investigator at the Massachusetts General Hospital and associate professor at Harvard Medical School, to discuss the function of CAVT and how it stands to revolutionize PE treatment.

“The CAVT is mechanical tech from Penumbra, used to remove blood clots from arteries and veins,” Rosovsky told 

. “What makes it unique is that it’s a minimally invasive procedure, and it uses a computer-powered algorithm to enable it to quickly detect what is clot and what’s not and then remove the clot and minimize blood loss. And in our study, we found that it was a safe and fast procedure.”

STORM-PE was a prospective, randomized, placebo-controlled trial conducted over 22 locations globally. For inclusion, patients were required to have clinical signs and symptoms of acute PE with a duration of ≤14 days, objectively confirmed acute PE based on computed tomographic pulmonary angiography (CTPA), and a classification of intermediate high-risk PE as demonstrated by right ventricular dysfunction RV/LV ratio ≥1 on CTPA, among other requirements. Exclusion criteria included hemodynamic instability with cardiac arrest, obstructive shock, or persistent hypotension and allergy-, hypersensitivity-, or heparin-induced thrombocytopenia.

A total of 100 patients were included in the trial and were randomly assigned in a 1:1 ratio to either CAVT (n = 47) or AC (n = 53). The mean age was 59.5 +/- 13.22 years in the CAVT arm and 61.2 +/- 14.19 years in the AC arm. The mean time from symptom onset to PE hospital admission was 3 days (interquartile range [IQR] 0-6) in the CAVT arm and 2 days (0-6) in the AC arm (

 = 0.889). All patients had elevated cardiac biomarkers, and 59.1% in the CAVT arm and 74.5% in the AC arm had both elevated troponin and BNP or NT-proBNP.

After 48 hours, the CAVT arm saw a significantly greater change in RV/LV ratio (0.52 +/- 0.37 vs 0.24 +/- 0.4), with a difference of 0.27 (95% CI, 0.12-0.43; 

 <.001). CAVT treatment also resulted in earlier normalization of vital signs, and there was little difference in major adverse events across both arms (CAVT 4.3% vs AC 7.5%; 

“I think that this is a game changer,” Rosovsky said. “This is a groundbreaking trial. It really allows patients to think about an alternative or additional therapy that can really help them feel better and improve faster.”

Editor’s Note: Rosovsky reports disclosures with BMS, Janssen, Dava, and Inari Medical.

Lookstein RA, Konstantinides SV, Weinberg I, et al. Randomized controlled trial of mechanical thrombectomy with anticoagulation versus anticoagulation alone for acute intermediate-high risk pulmonary embolism: Primary outcomes from the storm-PE trial. Circulation. Published online November 3, 2025. 

Penumbra Inc. Comparison of Two Pulmonary Embolism Treatments. ClinicalTrials.gov Identifier: NCT05684796. Updated November 17, 2025. Accessed November 25, 2025. 

https://clinicaltrials.gov/study/NCT05684796

Rosovsky discusses the revolutionary new therapy’s potential to revolutionize the field of pulmonary embolism treatment.

Venous Thromboembolism

The HCPLive venous thromboembolism page is a resource for medical news and expert insights on VTE. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for thrombotic disease, and more.

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

These new data indicate a potential lack of accuracy in hospital-based data on hidradenitis suppurativa (HS) outcomes among those in nonclinical settings.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Long-Term Course of HS Disease More Favorable Than Previous Estimates

Shagun Bindlish, MD, FACP, FOMA, DABOM, DACLM, is an internist and diabetologist with advanced expertise in obesity and lifestyle medicine. She serves as medical and scientific chair for the ADA Northern California and is the founder of the Golden State Obesity Society. An educator at Touro University California and University at Sea CME, she has trained providers worldwide in metabolic health. 

Recognized with the Obesity Medicine Association’s Outstanding Contribution Award in 2024, she is also nominated by her peers for the Compassionate Physician of the Year Award by the California Medical Association. Her work focuses on advancing diabetes and obesity care through innovation, education, and advocacy.

Shagun Bindlish, MD, emphasizes the urgent need to integrate diabetes and obesity care, addressing their shared metabolic roots for better health outcomes.

Type 2 Diabetes

Beyond Blood Sugar: Reframing Diabetes Awareness Through the Lens of Obesity

Michelle O'Donoghue, MD, is the McGillycuddy-Logue Endowed Chair in Cardiology at Brigham and Women's Hospital and associate professor at Harvard Medical School

O’Donoghue discusses the results of this analysis of the FOURIER trial, highlighting that no limit was found for lowered LDL-C improving MACE risk.

Atherosclerotic Cardiovascular Disease

Dyslipidemia

Very Low LDL-C Improves Risk of MACE in Patients With ASCVD, With Michelle O’Donoghue, MD

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

State- and local-level disparities in the availability of gastroenterologist care disproportionately affect patients with IBD and populations living in rural and high-poverty areas.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Geographic Disparities in GI Specialist Availability Suggest Limited Access to Care

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

However, a related editorial from University of Rome was quick to point out possibly sizable placebo effects in the trial.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Meta-analysis shows semaglutide lowers cardiovascular and kidney risks while supporting safety in adults with chronic kidney disease.


Semaglutide Provides Cardiorenal Benefits in CKD With or Without Diabetes

This global analysis highlights the incidence of psoriasis around the world by 2025, noting various distinctions in region, age groups, and sex.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Psoriasis Incidence Projected to Increase by 2025 Across Various Groups

Vinay Mehta, MD: Board-certified allergist/immunologist with Allergy & Asthma Associates of Southern California

Board-certified allergist shares how clinicians can better recognize and prevent atopic dermatitis in patients with skin of color, addressing pigmentation.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

How to Recognize and Treat Atopic Dermatitis in Patients with Skin of Color

Brandon Yan, MD, is a resident physician at the University of California.

Yan discusses the reversion of 50-year trends in mortality and the steps needed to reduce these rates back to pre-pandemic levels.

Cardiomyopathy

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Addressing Post-Pandemic Cardiovascular Mortality Rate Increases, With Brandon Yan, MD

This research, presented at the SDPA Fall Conference, highlights a consensus report proposing the first formal set of dermoscopy proficiency expectations for PAs.

Latest News

This Year in Medicine 2025: Recognizing Top Advances in Healthcare

INF904 Shows Strong Phase 2a Results in HS and CSU, With No Safety Signals

FDA Accepts sNDA for Furosemide Autoinjector for Chronic Heart Failure and CKD

Factor D Inhibition Lacks Efficacy For IgAN in Phase 2 ALXN2050 Trial, With Sayna Norouzi, MD

CAVT With Anticoagulation Substantially Reduces RV/LV Diameter Ratio in PE, With Rachel Rosovsky, MD